Priyathama Vellanki1, Karoline Lange, Dina Elaraj, Peter A Kopp, Malek El Muayed. 1. Division of Endocrinology, Metabolism, and Molecular Medicine (P.V., P.A.K., M.E.M.), Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611; Georg-August University of Göttingen (K.L.), 37073 Göttingen, Germany; and Division of Endocrine Surgery (D.E.), Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Abstract
CONTEXT: Most of the morbidity and mortality from parathyroid cancer is due to PTH-mediated hypercalcemia. Classically, management mainly consists of surgical resection, chemotherapy, and alleviation of hypercalcemia using bisphosphonates and calcium receptor agonists. The use of denosumab in the treatment of parathyroid cancer-mediated hypercalcemia has not been reported. OBJECTIVE: The aim of this report is to describe the effect of denosumab on parathyroid cancer-induced hypercalcemia. SUBJECT, MEASURES, AND RESULT: The patient is a 39-year-old man with metastatic parathyroid cancer who presented at age 35. His calcium levels initially responded to surgery, bisphosphonates, calcium receptor agonist, and chemotherapy (dacarbazine). However, his disease progressed, and his hypercalcemia became refractory to these measures in the setting of rising PTH levels. The addition of denosumab, a humanized monoclonal antibody inhibiting receptor activator of nuclear factor κB ligand resulted in successful management of his hypercalcemia for an additional 16 months. CONCLUSIONS: Denosumab can be effective in the treatment of refractory hypercalcemia in parathyroid cancer. It may also be of potential use in settings of benign hyperparathyroid-related hypercalcemia such as parathyromatosis, where hypercalcemia is not amenable to surgery or medical therapy with bisphosphonates and calcium receptor agonists.
CONTEXT: Most of the morbidity and mortality from parathyroid cancer is due to PTH-mediated hypercalcemia. Classically, management mainly consists of surgical resection, chemotherapy, and alleviation of hypercalcemia using bisphosphonates and calcium receptor agonists. The use of denosumab in the treatment of parathyroid cancer-mediated hypercalcemia has not been reported. OBJECTIVE: The aim of this report is to describe the effect of denosumab on parathyroid cancer-induced hypercalcemia. SUBJECT, MEASURES, AND RESULT: The patient is a 39-year-old man with metastatic parathyroid cancer who presented at age 35. His calcium levels initially responded to surgery, bisphosphonates, calcium receptor agonist, and chemotherapy (dacarbazine). However, his disease progressed, and his hypercalcemia became refractory to these measures in the setting of rising PTH levels. The addition of denosumab, a humanized monoclonal antibody inhibiting receptor activator of nuclear factor κB ligand resulted in successful management of his hypercalcemia for an additional 16 months. CONCLUSIONS:Denosumab can be effective in the treatment of refractory hypercalcemia in parathyroid cancer. It may also be of potential use in settings of benign hyperparathyroid-related hypercalcemia such as parathyromatosis, where hypercalcemia is not amenable to surgery or medical therapy with bisphosphonates and calcium receptor agonists.
Authors: David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: M T Collins; M C Skarulis; J P Bilezikian; S J Silverberg; A M Spiegel; S J Marx Journal: J Clin Endocrinol Metab Date: 1998-04 Impact factor: 5.958
Authors: Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245
Authors: Abdallah Roukain; Heba Alwan; Massimo Bongiovanni; Gerasimos P Sykiotis; Peter A Kopp Journal: Front Endocrinol (Lausanne) Date: 2022-01-31 Impact factor: 5.555
Authors: Reiner Jumpertz von Schwartzenberg; Ulf Elbelt; Manfred Ventz; Knut Mai; Tina Kienitz; Lukas Maurer; Thomas Rose; Jens C Rückert; Christian J Strasburger; Joachim Spranger Journal: Endocrinol Diabetes Metab Case Rep Date: 2015-10-29